[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100466487":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":30,"locations":38,"responsibleParty":55,"collaborators":57,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":19,"eligibilityCriteria":64,"healthyVolunteers":61,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":19,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":41,"whyStopped":19,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"The Affiliated Hospital of Xuzhou Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CAR-T cell immunotherapy","EXPERIMENTAL","The registered patients will receive CAR-T cell immunotherapy for the new specific chimeric antigen receptor of PSMA antigen by infusion.",[13],"Biological: CAR-T cell immunotherapy",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at PSMA.",[9],null,[21,24,27],{"name":22,"affiliation":5,"role":23},"Junnian Zheng, M.D\u002FPh.D","STUDY_DIRECTOR",{"name":25,"affiliation":5,"role":26},"Hailong Li, M.D\u002FPh.D","PRINCIPAL_INVESTIGATOR",{"name":28,"affiliation":29,"role":26},"Qing Zhang, Ph.D","Xuzhou Medical University",[31,35],{"name":25,"role":32,"phone":33,"phoneExt":19,"email":34},"CONTACT","0086-17798835021","Justinlee719@163.com",{"name":28,"role":32,"phone":36,"phoneExt":19,"email":37},"0086-516-83262238","qingzhang@xzhmu.edu.cn",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Affiliated Hospital of Xuzhou Medical University","RECRUITING","Xuzhou","Jiangsu","221000","China","CN",{"type":48,"coordinates":49},"Point",[50,51],117.28386,34.20442,{"lat":51,"lon":50},[54],{"name":25,"role":32,"phone":33,"phoneExt":19,"email":34},{"type":56,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[58],{"name":29,"class":6},"100466487","phase-1-clinical-study-of-psma-targeted-car-t-cells-in-the-treatment-of-castration-resistant-prostate-cancer-100466487",false,"NCT05354375","Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer","Inclusion Criteria:\n\n1. Male patients aged from 18 to 75 years old;\n2. The patients' ECOG score ≤ 2;\n3. Prostate cancer patients in castration resistance stage (with or without distant metastasis):\n\n   1. Previous new endocrine therapy is ineffective;\n   2. Past treatment with too much citabine or cabatase is ineffective.\n4. Have measurable or evaluable lesions;\n5. The patients' main tissues and organs function well:\n\n   1. Liver function: ALT\u002FAST \\\u003C 3 times the upper limit of normal value (ULN);\n   2. renal function: creatinine \\\u003C 220 μ mol\u002FL;\n   3. Lung function: indoor oxygen saturation ≥ 95%;\n   4. Cardiac function: Left ventricular ejection fraction (LVEF)≥40%\n6. Patients or their legal guardians voluntarily participate and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Infectious diseases (such as HIV, active hepatitis B or C infection, active tuberculosis, etc.);\n2. Feasibility evaluation screening proves that the transfection of targeted lymphocytes is less than 10% or the amplification under the co-stimulation of CD3\u002FCD28 is insufficient (\\\u003C 5 times);\n3. The vital signs are abnormal and those who cannot cooperate with the inspectors;\n4. Those with mental illness or mental illness who can't cooperate with treatment and curative effect evaluation;\n5. Highly allergic constitution or severe allergic history, especially those who are allergic to IL-2;\n6. Subjects with systemic infection or local severe infection who need anti-infection treatment;\n7. Complicated dysfunction of heart, lung, brain, liver, kidney and other important organs;\n8. Patients with other tumors;\n9. Doctors think that there are other reasons that can't be included in the treatment.","MALE","18 Years","75 Years",{"count":69,"type":70},20,"ESTIMATED","INTERVENTIONAL",[73],"PHASE1","This is an experimental study to evaluate the safety and effectiveness of PSMA-targeted CAR-T cells in the treatment of castration-resistant prostate cancer.",[76],"Immunotherapy",[78,79,80,81,82],"Prostate specific membrane antigen","Castration-resistant Prostate Cancer","CAR-T","Chimeric antigen receptor","T cell","2022-04-26",{"date":85,"type":86},"2022-04-29","ACTUAL",{"date":88,"type":70},"2022-12-01",{"date":90,"type":70},"2026-11-30",{"name":5,"class":6},1]